polyclonal rabbit anti human stmn1 ser38 antibody  (Cell Signaling Technology Inc)

Journal: Gland Surgery

Article Title: The prognostic role of a phospho-Stathmin 1 signature in breast cancer treated with neoadjuvant chemotherapy

doi: 10.21037/gs-22-628

Figure Lengend Snippet: Relationship between STMN1 and its phosphorylation-related proteins and clinical outcomes for breast cancer patients. (A) Relationship between Kaplan-Meier analysis of DFS and STMN1 level by IHC (400×). (B) Relationship between Kaplan-Meier analysis of DFS and STMN1 phosphorylation at Ser16 levelby IHC (400×). (C) Relationship between Kaplan-Meier analysis of DFS and STMN1 phosphorylation at Ser25 levelby IHC (400×). (D) Relationship between Kaplan-Meier analysis of DFS and STMN1 phosphorylation at Ser38 levelby IHC (400×). (E) Relationship between Kaplan-Meier analysis of DFS and STMN1 phosphorylation at Ser63 levelby IHC (400×). (F) Relationship between Kaplan-Meier analysis of DFS and GRP78 level by IHC (400×). DFS, disease-free survival.

Article Snippet: Polyclonal rabbit anti-human STMN1 Ser38 antibody (Cell Signaling Technologies) was diluted to 1:100 and incubated with samples in a humid chamber at 4 °C overnight. respectively.

Techniques: Phospho-proteomics

Journal: Gland Surgery

Article Title: The prognostic role of a phospho-Stathmin 1 signature in breast cancer treated with neoadjuvant chemotherapy

doi: 10.21037/gs-22-628

Figure Lengend Snippet: Relationship between STMN1 phosphorylation and pathologic response. (A) Correlation between pathologic response and STMN1 expression. (B) Correlation between pathologic response and STMN1 phosphorylation at Ser-16. (C) Correlation between pathologic response and STMN1 phosphorylation at Ser-25. (D) Correlation between pathologic response and STMN1 phosphorylation at Ser-38. (E) Correlation between pathologic response and STMN1 phosphorylation at Ser-63. (F) Correlation between pathologic response and GRP78. pCR, pathological complete response.

Article Snippet: Polyclonal rabbit anti-human STMN1 Ser38 antibody (Cell Signaling Technologies) was diluted to 1:100 and incubated with samples in a humid chamber at 4 °C overnight. respectively.

Techniques: Phospho-proteomics, Expressing

Journal: Gland Surgery

Article Title: The prognostic role of a phospho-Stathmin 1 signature in breast cancer treated with neoadjuvant chemotherapy

doi: 10.21037/gs-22-628

Figure Lengend Snippet: p-STMN1/GRP78 model powerfully predicts DFS for patients treated with NACT. (A) Kaplan-Meier analysis of DFS in breast cancer patients from high and low-risk groups classified by the p-STMN1/GRP78 model. (B) ROC curves to test the prognostic accuracy of the p-STMN1/GRP78 model. DFS, disease-free survival; ROC, receiver operating characteristic; AUC, area under the receiver operating characteristic curve.

Article Snippet: Polyclonal rabbit anti-human STMN1 Ser38 antibody (Cell Signaling Technologies) was diluted to 1:100 and incubated with samples in a humid chamber at 4 °C overnight. respectively.

Techniques:

Journal: Oncotarget

Article Title: Stathmin and phospho-stathmin protein signature is associated with survival outcomes of breast cancer patients

doi:

Figure Lengend Snippet: A. Representative IHC staining of high and low expression of STMN1 in the large (400×) and small images (100×). B. Representative IHC staining of high and low expression of multiple phosphor-sites (Ser-16, Ser-25, Ser38, Ser63) in the large (400×) and small images (100×). C. Kaplan-Meier analysis of DFS in the training set. D. Kaplan-Meier analysis of DFS in the validation set.

Article Snippet: For STMN1 and Ser38, TMAs were blocked with 10% normal goat serum for 1 h at room temperature (RT) and incubated in a humid chamber at 4°C overnight with polyclonal rabbit anti-human STMN1 antibody (Proteintech) or polyclonal rabbit anti-human STMN1 Ser38 (Cell Signaling Technologies) antibody diluted to 1:400 or 1:100, respectively.

Techniques: Immunohistochemistry, Expressing, Biomarker Discovery

Journal: Oncotarget

Article Title: Stathmin and phospho-stathmin protein signature is associated with survival outcomes of breast cancer patients

doi:

Figure Lengend Snippet: Univariate association of the STMN1-E/P model, clinicopathological characteristics, and single phospho-sites status with disease-free survival

Article Snippet: For STMN1 and Ser38, TMAs were blocked with 10% normal goat serum for 1 h at room temperature (RT) and incubated in a humid chamber at 4°C overnight with polyclonal rabbit anti-human STMN1 antibody (Proteintech) or polyclonal rabbit anti-human STMN1 Ser38 (Cell Signaling Technologies) antibody diluted to 1:400 or 1:100, respectively.

Techniques: Biomarker Discovery

Journal: Oncotarget

Article Title: Stathmin and phospho-stathmin protein signature is associated with survival outcomes of breast cancer patients

doi:

Figure Lengend Snippet: Data are shown as AUC (95% CI) or hazard ratios (95% CI). ROC = receiver operator characteristic. AUC = area under the curve. A. Comparisons of the prognostic accuracy by the STMN1-E/P model and TNM stage in the training set. B. DFS of patients with high- or low-risk scores in the training set. C. Comparisons of the prognostic accuracy by the STMN1-E/P model and TNM stage in the validation set. D. DFS of patients with high- or low-risk scores in the validation set. P values were calculated using the log-rank test.

Article Snippet: For STMN1 and Ser38, TMAs were blocked with 10% normal goat serum for 1 h at room temperature (RT) and incubated in a humid chamber at 4°C overnight with polyclonal rabbit anti-human STMN1 antibody (Proteintech) or polyclonal rabbit anti-human STMN1 Ser38 (Cell Signaling Technologies) antibody diluted to 1:400 or 1:100, respectively.

Techniques: Biomarker Discovery

Journal: Oncotarget

Article Title: Stathmin and phospho-stathmin protein signature is associated with survival outcomes of breast cancer patients

doi:

Figure Lengend Snippet: A. Comparisons of the prognostic accuracy by the STMN1-E/P/C model, STMN1-E/P model and TNM stage in the training set. B. DFS of patients with high- or low-risk scores according to the STMN1-E/P/C model in the training set. C. Comparisons of the prognostic accuracy by the STMN1-E/P/C model, STMN1-E/P model and TNM stage in the validation set. D. DFS of patients with high- or low-risk scores according to the STMN1-E/P/C model in the validation set. P values were calculated using the log-rank test. E. DFS of patients with luminal breast cancer. F. DFS of patients with HER2/neu subtype breast cancer. G. DFS of patients with TNBC subtype breast cancer.

Article Snippet: For STMN1 and Ser38, TMAs were blocked with 10% normal goat serum for 1 h at room temperature (RT) and incubated in a humid chamber at 4°C overnight with polyclonal rabbit anti-human STMN1 antibody (Proteintech) or polyclonal rabbit anti-human STMN1 Ser38 (Cell Signaling Technologies) antibody diluted to 1:400 or 1:100, respectively.

Techniques: Biomarker Discovery

Journal: Oncotarget

Article Title: Stathmin and phospho-stathmin protein signature is associated with survival outcomes of breast cancer patients

doi:

Figure Lengend Snippet: A. Representative IHC staining of high and low expression of STMN1 in the large (400×) and small images (100×). B. Representative IHC staining of high and low expression of multiple phosphor-sites (Ser-16, Ser-25, Ser38, Ser63) in the large (400×) and small images (100×). C. Kaplan-Meier analysis of DFS in the training set. D. Kaplan-Meier analysis of DFS in the validation set.

Article Snippet: For STMN1 and Ser38, TMAs were blocked with 10% normal goat serum for 1 h at room temperature (RT) and incubated in a humid chamber at 4°C overnight with polyclonal rabbit anti-human STMN1 antibody (Proteintech) or polyclonal rabbit anti-human STMN1 Ser38 (Cell Signaling Technologies) antibody diluted to 1:400 or 1:100, respectively.

Techniques: Immunohistochemistry, Expressing, Biomarker Discovery

Journal: Oncotarget

Article Title: Stathmin and phospho-stathmin protein signature is associated with survival outcomes of breast cancer patients

doi:

Figure Lengend Snippet: Univariate association of the STMN1-E/P model, clinicopathological characteristics, and single phospho-sites status with disease-free survival

Article Snippet: For STMN1 and Ser38, TMAs were blocked with 10% normal goat serum for 1 h at room temperature (RT) and incubated in a humid chamber at 4°C overnight with polyclonal rabbit anti-human STMN1 antibody (Proteintech) or polyclonal rabbit anti-human STMN1 Ser38 (Cell Signaling Technologies) antibody diluted to 1:400 or 1:100, respectively.

Techniques: Biomarker Discovery

Journal: Oncotarget

Article Title: Stathmin and phospho-stathmin protein signature is associated with survival outcomes of breast cancer patients

doi:

Figure Lengend Snippet: Data are shown as AUC (95% CI) or hazard ratios (95% CI). ROC = receiver operator characteristic. AUC = area under the curve. A. Comparisons of the prognostic accuracy by the STMN1-E/P model and TNM stage in the training set. B. DFS of patients with high- or low-risk scores in the training set. C. Comparisons of the prognostic accuracy by the STMN1-E/P model and TNM stage in the validation set. D. DFS of patients with high- or low-risk scores in the validation set. P values were calculated using the log-rank test.

Article Snippet: For STMN1 and Ser38, TMAs were blocked with 10% normal goat serum for 1 h at room temperature (RT) and incubated in a humid chamber at 4°C overnight with polyclonal rabbit anti-human STMN1 antibody (Proteintech) or polyclonal rabbit anti-human STMN1 Ser38 (Cell Signaling Technologies) antibody diluted to 1:400 or 1:100, respectively.

Techniques: Biomarker Discovery

Journal: Oncotarget

Article Title: Stathmin and phospho-stathmin protein signature is associated with survival outcomes of breast cancer patients

doi:

Figure Lengend Snippet: A. Comparisons of the prognostic accuracy by the STMN1-E/P/C model, STMN1-E/P model and TNM stage in the training set. B. DFS of patients with high- or low-risk scores according to the STMN1-E/P/C model in the training set. C. Comparisons of the prognostic accuracy by the STMN1-E/P/C model, STMN1-E/P model and TNM stage in the validation set. D. DFS of patients with high- or low-risk scores according to the STMN1-E/P/C model in the validation set. P values were calculated using the log-rank test. E. DFS of patients with luminal breast cancer. F. DFS of patients with HER2/neu subtype breast cancer. G. DFS of patients with TNBC subtype breast cancer.

Article Snippet: For STMN1 and Ser38, TMAs were blocked with 10% normal goat serum for 1 h at room temperature (RT) and incubated in a humid chamber at 4°C overnight with polyclonal rabbit anti-human STMN1 antibody (Proteintech) or polyclonal rabbit anti-human STMN1 Ser38 (Cell Signaling Technologies) antibody diluted to 1:400 or 1:100, respectively.

Techniques: Biomarker Discovery